Description
RaltegravirisanantiviralcompoundthatinhibitsHIVintegrase;itisclinicallyusedtotreatHIVinfection.Inpre-clinicalmodels,raltegravirdecreasesinfectionratesbypreventinginsertionofHIV-1DNAintothehostgenome.
RaltegravirisanantiviralcompoundthatinhibitsHIVintegrase;itisclinicallyusedtotreatHIVinfection.Inpre-clinicalmodels,raltegravirdecreasesinfectionratesbypreventinginsertionofHIV-1DNAintothehostgenome.
| CasNo. | 518048-05-0 |
|---|---|
| Purity | ≥99% |
| Formula | C20H21FN6O5 |
| FormulaWt. | 444.42 |
| IUPACName | N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxADIazol-2-yl)carbonyl]amino}-2-propanyl)-6-oxo-1,6-dihydro-4-pyrimidinecarboxamide |
| Synonym | MK-0518 |
| Appearance | Whitetooffwhitepowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | R0247InfoSheetPDF |
|---|---|
| Brochures | AntiviralsBooklet |
TaramassoL,MadedduG,RicciE,etal.Raltegravir-basedtherapyinacohortofHIV/HCVco-infectedindividuals.BiomedPharmacother.2015Feb;69:233-6.PMID:25661363.
MouscadetJF,TchertanovL.Raltegravir:molecularbasisofitsmechanismofaction.EurJMedRes.2009Nov24;14Suppl3:5-16.PMID:19959411.
HicksC,GulickRM.Raltegravir:thefirstHIVtype1integraseinhibitor.ClinInfectDis.2009Apr1;48(7):931-9.PMID:19231980.